This promotional webinar series has been initiated and funded by Idorsia Pharmaceuticals UK Ltd and is intended for UK healthcare professionals only.

2026 series overview: turning learning into improved patient outcomes

Join us to reflect on highlights and key takeaways from across the webinar series. Dr Hare and Dr Schaedel will explore practical insights from across the full programme and discuss how to implement this learning in clinical practice. They'll also look at the role of QUVIVIQ® (daridorexant) in the management pathway for chronic insomnia in diverse adult populations.

This webinar will discuss QUVIVIQ (daridorexant), manufactured by Idorsia Pharmaceuticals.

1 CPD hour

Click here to view prescribing information and adverse event reporting information

QUVIVIQ (daridorexant) is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.1

1. QUVIVIQ Idorsia Pharmaceuticals Ltd, summary of product characteristics

Curious to see past webinars?

All past events in the Beyond Sleepless Nights series are available as on-demand learning modules to complete at your own pace, with CPD hours available.

Discover more on MIMS Learning